表紙
市場調查報告書
商品編碼
1005351

子宮內膜異位症治療藥的全球市場(2021年∼2025年)

Global Endometriosis Drugs Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

子宮內膜異位症治療藥的市場規模在2021年∼2025年間預計將以超越3%的年複合成長率推移,並成長到3億3,272萬美元。

子宮內膜異位症藥市場相關之本報告提供整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

該市場成長的主要因素有近幾年批准的先進診斷技術。

本報告提供子宮內膜異位症治療藥市場調查,提供市場概要,市場規模,市場預測,客戶形勢,各產品·各地區的分析,再加上業者情勢和供應商分析等資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2020年
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

各產品的市場區隔

  • 市場·市場區隔
  • 各產品比較
  • 荷爾蒙療法:市場規模與預測(2020年∼2025年)
  • 止痛藥:市場規模與預測(2020年∼2025年)
  • 各產品的市場機會

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2020年∼2025年)
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 其他地區(ROW):市場規模與預測(2020年∼2025年)
  • 美國:市場規模與預測(2020年∼2025年)
  • 英國:市場規模與預測(2020年∼2025年)
  • 日本:市場規模與預測(2020年∼2025年)
  • 德國:市場規模與預測(2020年∼2025年)
  • 加拿大:市場規模與預測(2020年∼2025年)
  • 地區的市場機會

推動要素,課題,及趨勢

  • 市場推動因素
  • 市場課題
  • 成長要素與課題的影響
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Debiopharm International SA
  • Gedeon Richter Plc
  • Mayne Pharma Group Ltd.
  • Merck and Co. Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR70538

Technavio has been monitoring the endometriosis drugs market and it is poised to grow by USD 332.72 million during 2021-2025, progressing at a CAGR of over 3% during the forecast period. Our report on the endometriosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by recent approvals of advanced diagnostics and it is anticipated to boost the growth of the market as well.

The endometriosis drugs market analysis includes the product segment and geographic landscape.

Technavio's endometriosis drugs market is segmented as below:

By Product

  • Hormone therapy
  • Analgesics

By Geographic

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the strategic alliances as one of the prime reasons driving the endometriosis drugs market growth during the next few years. Also, strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on endometriosis drugs market covers the following areas:

  • Endometriosis drugs market sizing
  • Endometriosis drugs market forecast
  • Endometriosis drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endometriosis drugs market vendors that include AbbVie Inc., AstraZeneca Plc, Bayer AG, Debiopharm International SA, Gedeon Richter Plc, Mayne Pharma Group Ltd., Merck and Co. Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the endometriosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

Executive Summary

  • Market overview

Market Landscape

  • Market ecosystem

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020-2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Hormone therapy - Market size and forecast 2020-2025
  • Analgesics - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer Landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • Rest of World (ROW) - Market size and forecast 2020-2025
  • US - Market size and forecast 2020-2025
  • UK - Market size and forecast 2020-2025
  • Japan - Market size and forecast 2020-2025
  • Germany - Market size and forecast 2020-2025
  • Canada - Market size and forecast 2020-2025
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Market challenges
  • Impact of drivers and challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Debiopharm International SA
  • Gedeon Richter Plc
  • Mayne Pharma Group Ltd.
  • Merck and Co. Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Inclusions and exclusions checklist
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

  • 1: Key finding 1
  • 2: Key finding 1
  • 3: Key finding 2
  • 4: Key finding 3
  • 5: Key finding 4
  • 6: Key finding 5
  • 7: Key finding 5
  • 8: Key finding 6
  • 9: Market characteristics
  • 10: Parent market
  • 11: Offerings of vendors included in the market definition
  • 12: Market segments
  • 13: Global - Market size and forecast 2020-2025 ($ million)
  • 14: Global - Market size and forecast 2020-2025 ($ million)
  • 15: Global Market: Year-over-year growth 2020-2025 (%)
  • 16: Global Market: Year-over-year growth 2020-2025 (%)
  • 17: Five forces analysis 2020 and 2025
  • 18: Bargaining power of buyers
  • 19: Bargaining power of suppliers
  • 20: Threat of new entrants
  • 21: Threat of substitutes
  • 22: Threat of rivalry
  • 23: Market condition - Five forces 2020 and 2025
  • 24: Product - Market share 2020-2025 (%)
  • 25: Product - Market share 2020-2025 (%)
  • 26: Comparison by Product
  • 27: Comparison by Product
  • 28: Hormone therapy - Market size and forecast 2020-2025 ($ million)
  • 29: Hormone therapy - Market size and forecast 2020-2025 ($ million)
  • 30: Hormone therapy - Year-over-year growth 2020-2025 (%)
  • 31: Hormone therapy - Year-over-year growth 2020-2025 (%)
  • 32: Analgesics - Market size and forecast 2020-2025 ($ million)
  • 33: Analgesics - Market size and forecast 2020-2025 ($ million)
  • 34: Analgesics - Year-over-year growth 2020-2025 (%)
  • 35: Analgesics - Year-over-year growth 2020-2025 (%)
  • 36: Market opportunity by Product ($ million)
  • 37: Customer landscape
  • 38: Market share by geography 2020-2025 (%)
  • 39: Market share by geography 2020-2025 (%)
  • 40: Geographic comparison
  • 41: Geographic comparison
  • 42: North America - Market size and forecast 2020-2025 ($ million)
  • 43: North America - Market size and forecast 2020-2025 ($ million)
  • 44: North America - Year-over-year growth 2020-2025 (%)
  • 45: North America - Year-over-year growth 2020-2025 (%)
  • 46: Europe - Market size and forecast 2020-2025 ($ million)
  • 47: Europe - Market size and forecast 2020-2025 ($ million)
  • 48: Europe - Year-over-year growth 2020-2025 (%)
  • 49: Europe - Year-over-year growth 2020-2025 (%)
  • 50: Asia - Market size and forecast 2020-2025 ($ million)
  • 51: Asia - Market size and forecast 2020-2025 ($ million)
  • 52: Asia - Year-over-year growth 2020-2025 (%)
  • 53: Asia - Year-over-year growth 2020-2025 (%)
  • 54: Rest of World (ROW) - Market size and forecast 2020-2025 ($ million)
  • 55: Rest of World (ROW) - Market size and forecast 2020-2025 ($ million)
  • 56: Rest of World (ROW) - Year-over-year growth 2020-2025 (%)
  • 57: Rest of World (ROW) - Year-over-year growth 2020-2025 (%)
  • 58: US - Market size and forecast 2020-2025 ($ million)
  • 59: US - Market size and forecast 2020-2025 ($ million)
  • 60: US - Year-over-year growth 2020-2025 (%)
  • 61: UK - Market size and forecast 2020-2025 ($ million)
  • 62: UK - Market size and forecast 2020-2025 ($ million)
  • 63: UK - Year-over-year growth 2020-2025 (%)
  • 64: Japan - Market size and forecast 2020-2025 ($ million)
  • 65: Japan - Market size and forecast 2020-2025 ($ million)
  • 66: Japan - Year-over-year growth 2020-2025 (%)
  • 67: Germany - Market size and forecast 2020-2025 ($ million)
  • 68: Germany - Market size and forecast 2020-2025 ($ million)
  • 69: Germany - Year-over-year growth 2020-2025 (%)
  • 70: Canada - Market size and forecast 2020-2025 ($ million)
  • 71: Canada - Market size and forecast 2020-2025 ($ million)
  • 72: Canada - Year-over-year growth 2020-2025 (%)
  • 73: Market opportunity by geography
  • 74: Impact of drivers and challenges
  • 75: Vendor landscape
  • 76: Industry risks
  • 77: Landscape disruption
  • 78: Vendors covered
  • 79: Market positioning of vendors
  • 80: AbbVie Inc. - Overview
  • 81: AbbVie Inc. - Product / Service
  • 82: AbbVie Inc. - Key news
  • 83: AbbVie Inc. - Key offerings
  • 84: AstraZeneca Plc - Overview
  • 85: AstraZeneca Plc - Product / Service
  • 86: AstraZeneca Plc - Key news
  • 87: AstraZeneca Plc - Key offerings
  • 88: Bayer AG - Overview
  • 89: Bayer AG - Business segments
  • 90: Bayer AG - Key news
  • 91: Bayer AG - Key offerings
  • 92: Bayer AG - Segment focus
  • 93: Debiopharm International SA - Overview
  • 94: Debiopharm International SA - Product / Service
  • 95: Debiopharm International SA - Key news
  • 96: Debiopharm International SA - Key offerings
  • 97: Gedeon Richter Plc - Overview
  • 98: Gedeon Richter Plc - Business segments
  • 99: Gedeon Richter Plc - Key news
  • 100: Gedeon Richter Plc - Key offerings
  • 101: Gedeon Richter Plc - Segment focus
  • 102: Mayne Pharma Group Ltd. - Overview
  • 103: Mayne Pharma Group Ltd. - Business segments
  • 104: Mayne Pharma Group Ltd. - Key news
  • 105: Mayne Pharma Group Ltd. - Key offerings
  • 106: Mayne Pharma Group Ltd. - Segment focus
  • 107: Merck and Co. Inc. - Overview
  • 108: Merck and Co. Inc. - Business segments
  • 109: Merck and Co. Inc. - Key news
  • 110: Merck and Co. Inc. - Key offerings
  • 111: Merck and Co. Inc. - Segment focus
  • 112: Pfizer Inc. - Overview
  • 113: Pfizer Inc. - Business segments
  • 114: Pfizer Inc. - Key news
  • 115: Pfizer Inc. - Key offerings
  • 116: Pfizer Inc. - Segment focus
  • 117: Takeda Pharmaceutical Co. Ltd. - Overview
  • 118: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • 119: Takeda Pharmaceutical Co. Ltd. - Key news
  • 120: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 121: Teva Pharmaceutical Industries Ltd. - Overview
  • 122: Teva Pharmaceutical Industries Ltd. - Business segments
  • 123: Teva Pharmaceutical Industries Ltd. - Key news
  • 124: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 125: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 126: Inclusions checklist
  • 127: Exclusions checklist
  • 128: Currency conversion rates for US$
  • 129: Research methodology
  • 130: Validation techniques employed for market sizing
  • 131: Information sources
  • 132: List of abbreviations